• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Instil Bio

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
September 16, 2024
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
August 01, 2024
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 10, 2024
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Strategic Update
January 16, 2024
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 05, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 31, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
January 09, 2023
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 08, 2022
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2022
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
October 31, 2022
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
October 18, 2022
From Instil Bio
Via GlobeNewswire
Tickers TIL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap